Eli Lilly Raises 2026 Revenue Outlook to $91 Billion to $92 Billion

Eli Lilly raised its 2026 revenue forecast to $91 billion to $92 billion after third-quarter revenue rose 39% to $24.397 billion, powered by sales growth for Mounjaro and Zepbound.

Revenue was up from $17.601 billion a year earlier. Mounjaro sales increased 65% to $10.7 billion, and Zepbound generated $5.35 billion. The results followed a preview of Lilly’s third-quarter earnings.

Lilly’s updated revenue range compares with its previous forecast of $85 billion to $87 billion. The company reported non-GAAP earnings per share of $7.48.

The company set its 2026 non-GAAP earnings-per-share outlook at $35 to $36, down from its previous range of $35.50 to $36.50. The revised outlook partly reflects $4.57 per share in acquired in-process research and development charges.

Foundayo sales totaled $184 million.